H-H Chen1, Y J Tseng2, S-Y Wang3, Y-S Tsai4, C-S Chang5, T-C Kuo6, W-J Yao7, C-C Shieh4, C-H Wu8, P-H Kuo9. 1. Department of Public Health and Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan. 2. 1] School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan [2] Department of Computer Science and Information Engineering, National Taiwan University, Taipei, Taiwan [3] Graduate Institute of Biomedical Electronic and Bioinformatics, National Taiwan University, Taipei, Taiwan [4] The Metabolomics Core Laboratory, Center of Genomic Medicine, National Taiwan University, Taipei, Taiwan. 3. 1] Department of Computer Science and Information Engineering, National Taiwan University, Taipei, Taiwan [2] The Metabolomics Core Laboratory, Center of Genomic Medicine, National Taiwan University, Taipei, Taiwan. 4. Institute of Clinical Medicine, National Cheng Kung University Medical College, Tainan, Taiwan. 5. 1] Institute of Clinical Medicine, National Cheng Kung University Medical College, Tainan, Taiwan [2] Department of Family Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. 6. 1] Graduate Institute of Biomedical Electronic and Bioinformatics, National Taiwan University, Taipei, Taiwan [2] The Metabolomics Core Laboratory, Center of Genomic Medicine, National Taiwan University, Taipei, Taiwan. 7. Department of Nuclear Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. 8. 1] Department of Family Medicine, National Cheng Kung University Hospital, Tainan, Taiwan [2] Institute of Behavioral Medicine, National Cheng Kung University Medical College, Tainan, Taiwan. 9. 1] Department of Public Health and Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan [2] Research Center for Genes, Environment and Human Health, National Taiwan University, Taipei, Taiwan.
Abstract
OBJECTIVES: Mechanisms of the development of abnormal metabolic phenotypes among obese population are not yet clear. In this study, we aimed to screen metabolomes of both healthy and subjects with abnormal obesity to identify potential metabolic pathways that may regulate the different metabolic characteristics of obesity. METHODS: We recruited subjects with body mass index (BMI) over 25 from the weight-loss clinic of a central hospital in Taiwan. Metabolic healthy obesity (MHO) is defined as without having any form of hyperglycemia, hypertension and dyslipidemia, while metabolic abnormal obesity (MAO) is defined as having one or more abnormal metabolic indexes. Serum-based metabolomic profiling using both liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry of 34 MHO and MAO individuals with matching age, sex and BMI was performed. Conditional logistic regression and partial least squares discriminant analysis were applied to identify significant metabolites between the two groups. Pathway enrichment and topology analyses were conducted to evaluate the regulated pathways. RESULTS: A differential metabolite panel was identified to be significantly differed in MHO and MAO groups, including L-kynurenine, glycerophosphocholine (GPC), glycerol 1-phosphate, glycolic acid, tagatose, methyl palmitate and uric acid. Moreover, several metabolic pathways were relevant in distinguishing MHO from MAO groups, including fatty acid biosynthesis, phenylalanine metabolism, propanoate metabolism, and valine, leucine and isoleucine degradation. CONCLUSION: Different metabolomic profiles and metabolic pathways are important for distinguishing between MHO and MAO groups. We have identified and discussed the key metabolites and pathways that may prove important in the regulation of metabolic traits among the obese, which could provide useful clues to study the underlying mechanisms of the development of abnormal metabolic phenotypes.
OBJECTIVES: Mechanisms of the development of abnormal metabolic phenotypes among obese population are not yet clear. In this study, we aimed to screen metabolomes of both healthy and subjects with abnormal obesity to identify potential metabolic pathways that may regulate the different metabolic characteristics of obesity. METHODS: We recruited subjects with body mass index (BMI) over 25 from the weight-loss clinic of a central hospital in Taiwan. Metabolic healthy obesity (MHO) is defined as without having any form of hyperglycemia, hypertension and dyslipidemia, while metabolic abnormal obesity (MAO) is defined as having one or more abnormal metabolic indexes. Serum-based metabolomic profiling using both liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry of 34 MHO and MAO individuals with matching age, sex and BMI was performed. Conditional logistic regression and partial least squares discriminant analysis were applied to identify significant metabolites between the two groups. Pathway enrichment and topology analyses were conducted to evaluate the regulated pathways. RESULTS: A differential metabolite panel was identified to be significantly differed in MHO and MAO groups, including L-kynurenine, glycerophosphocholine (GPC), glycerol 1-phosphate, glycolic acid, tagatose, methyl palmitate and uric acid. Moreover, several metabolic pathways were relevant in distinguishing MHO from MAO groups, including fatty acid biosynthesis, phenylalanine metabolism, propanoate metabolism, and valine, leucine and isoleucine degradation. CONCLUSION: Different metabolomic profiles and metabolic pathways are important for distinguishing between MHO and MAO groups. We have identified and discussed the key metabolites and pathways that may prove important in the regulation of metabolic traits among the obese, which could provide useful clues to study the underlying mechanisms of the development of abnormal metabolic phenotypes.
Authors: Rachel P Wildman; Paul Muntner; Kristi Reynolds; Aileen P McGinn; Swapnil Rajpathak; Judith Wylie-Rosett; MaryFran R Sowers Journal: Arch Intern Med Date: 2008-08-11
Authors: Wolfram Goessling; Joseph M Massaro; Ramachandran S Vasan; Ralph B D'Agostino; R Curtis Ellison; Caroline S Fox Journal: Gastroenterology Date: 2008-09-20 Impact factor: 22.682
Authors: Miguel Á Martínez-González; Miguel Ruiz-Canela; Adela Hruby; Liming Liang; Antonia Trichopoulou; Frank B Hu Journal: J Nutr Date: 2015-04-01 Impact factor: 4.798
Authors: Kristen D Brantley; Oana A Zeleznik; Barbra A Dickerman; Raji Balasubramanian; Clary B Clish; Julian Avila-Pacheco; Bernard Rosner; Rulla M Tamimi; A Heather Eliassen Journal: Br J Cancer Date: 2022-06-18 Impact factor: 9.075
Authors: Ueli Bütikofer; David Burnand; Reto Portmann; Carola Blaser; Flurina Schwander; Katrin A Kopf-Bolanz; Kurt Laederach; René Badertscher; Barbara Walther; Guy Vergères Journal: Metabolites Date: 2021-06-16